LHRH antagonist protocols in IVF do not lead to worse results than the long LHRH agonist protocol

References en Gynecologie Obstetrique

Volumn 7, Issue 4-5, 2000, Pages 249-250

  Ludwig, M ^a   Felberbaum, R E ^a   Diedrich, K ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; CETRORELIX; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; TRIPTORELIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; EMBRYO TRANSFER; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; PREGNANCY RATE; REVIEW;

EID: 0033674784     PISSN: 12448168     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Controlled ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the LHRH-antagonist Cetrorelix (Cetrotide) and the LHRH-agonist Buserelin
2. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
3. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH). Antagonist Cetrorelix at different dosages
4. Controlled ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the LHRH-antagonist Cetrorelix (Cetrotide®) according to the multiple dose protocol - Results of a prospective non controlled phase III study
5. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles
6. Ethical problems of the German Embryo Protection Law
7. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix in controlled ovarian stimulation for assisted reproduction
8. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial
9. A prospective randomized controlled study in IVF-ET with a single dose of a LH-RH antagonist (Cetrorelix) or a depot formula of a LH-RH agonist (Triptorelin)
10. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)